3-(3-methylphenyl)-N-prop-2-enylpropan-1-amine | 1415410-78-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(3-methylphenyl)-N-prop-2-enylpropan-1-amine
• CAS: 1415410-78-4
• 化学式: C₁₃H₁₉N
• 分子量: 189.301
• InChiKey: MJDAPFKFDNOBFN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-(3-methylphenyl)-N-prop-2-enylpropan-1-amine 在 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 、 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 20.0h， 生成 3-[2-oxo-1-(3-m-tolyl-propyl)-2,5-dihydro-1H-pyrrol-3-yl]-propionic acid methyl ester
  参考文献：
  名称：

  Property-Based Optimization of Hydroxamate-Based γ-Lactam HDAC Inhibitors to Improve Their Metabolic Stability and Pharmacokinetic Profiles

  摘要：

  Hydroxamate-based HDAC inhibitors have promising anticancer activities but metabolic instability and poor pharmacokinetics leading to poor in vivo results. QSAR and PK studies of HDAC inhibitors showed that a gamma-lactam core and a modified cap group, including halo, alkyl, and alkoxy groups with various carbon chain linkers, improved HDAC inhibition and metabolic stability. The biological properties of the gamma-lactam HDAC inhibitors were evaluated; the compound designated 8f had potent anticancer activity and high oral bioavailability.

  DOI：

  10.1021/jm3009376

文献信息

• Lactam-Based HDAC Inhibitors for Anticancer Chemotherapy: Restoration of RUNX3 by Posttranslational Modification and Epigenetic Control
  作者：Misun Cho、Eunhyun Choi、Jae Hyun Kim、Hwan Kim、Hwan Mook Kim、Jang Ik Lee、Ki-Chul Hwang、Hyun-Jung Kim、Gyoonhee Han

  DOI：10.1002/cmdc.201300393

  日期：2014.3

  transcription factor 3 (RUNX3) are regulated by histone deacetylase (HDAC). HDAC inhibition alters epigenetic and posttranslational stability of RUNX3, leading to tumor suppression. However, HDAC inhibitors can nonselectively alter global gene expression through chromatin remodeling. Thus, lactam‐based HDAC inhibitors were screened to identify potent protein stabilizers that maintain RUNX3 stability by acetylation

  肿瘤抑制子相关转录因子3（RUNX3）的表达和稳定性受组蛋白脱乙酰基酶（HDAC）调节。HDAC抑制会改变RUNX3的表观遗传和翻译后稳定性，从而导致肿瘤抑制。但是，HDAC抑制剂可以通过染色质重塑非选择性地改变全局基因的表达。因此，筛选了基于内酰胺的HDAC抑制剂以鉴定有效的蛋白质稳定剂，该稳定剂可通过乙酰化保持RUNX3的稳定性。通过基于细胞的RUNX激活和HDAC抑制测定法确定了111种基于内酰胺的类似物的RUNX活性和HDAC抑制作用。3- [1-（4-溴苄基）-2-氧代-2,5-二氢-1 H-吡咯-3-基] -N-羟基丙酰胺（11-8）可显着提高RUNX3的乙酰化和稳定性，并具有相对较低的RUNX3 mRNA表达和HDAC抑制活性。在MKN28异种移植模型中，该化合物显示出显着的抗肿瘤作用，比SAHA强。因此，我们提出了一种新的策略，其中HDAC抑制剂用作选择性靶向RUNX3的表
• A USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
  申请人：Korea Research Institute of Bioscience and Biotechnology

  公开号：EP1663201A1

  公开（公告）日：2006-06-07
• [EN] A USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME<br/>[FR] UTILISATION DE NOUVEAUX COMPOSES 2-OXO-HETEROCYCLIQUES ET COMPOSITIONS PHARMACEUTIQUES CONTENANT CES COMPOSES
  申请人：KOREA RES INST OF BIOSCIENCE

  公开号：WO2005004861A1

  公开（公告）日：2005-01-20

  [EN] The present invention is related to novel use of 2-oxo-heterocyclic compounds having anticancer activity and the process for preparing them and a pharmaceutical composition comprising the same. The present invention provides a pharmaceutical composition for preventing and treating the cancer disease comprising lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head and neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer or cancer of the anal region, stomach cancer, colon cancer, breast cancer, gynecologic tumors, Hodgkin's disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, sarcomas of soft tissues, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, solid tumors of childhood, lymphocytic lymphonas, cancer of the bladder, cancer of the kidney or ureter, or neoplasms of the central nervous system, therefore, it can be used as the therapeutics for treating and preventing cancer diseases.
  [FR] L'invention concerne une nouvelle utilisation de composés 2-oxo-hétérocycliques présentant une activité anticancéreuse, ainsi que le procédé permettant de préparer ces composés et une composition pharmaceutique les contenant. L'invention concerne également une composition pharmaceutique destinée à la prévention et au traitement des pathologies cancéreuses, notamment des cancers des poumons, des cancers osseux, des cancers du pancréas, des cancers de la peau, des cancers affectant la tête et le cou, des mélanomes cutanés ou intraoculaires, des cancers utérins, des cancers de l'ovaire, des cancers du rectum ou de la région anale, des cancers de l'estomac, du colon, du sein et des tumeurs gynécologiques, de la maladie de Hodgkin, des cancers de l'oesophage, de l'intestin grêle, du système endocrinien, des sarcomes des tissus mous, des cancers de l'urètre, du pénis, de la prostate, des leucémies chroniques ou aiguës, des tumeurs solides de l'enfant, des lymphomes lymphocytiques, des cancers de la vessie, des cancers des reins ou de l'uretère, ou des néoplasmes du système nerveux central, et indiquée par conséquent pour le traitement ou la prévention des pathologies cancéreuses.
• Property-Based Optimization of Hydroxamate-Based γ-Lactam HDAC Inhibitors to Improve Their Metabolic Stability and Pharmacokinetic Profiles
  作者：Eunhyun Choi、Chulho Lee、Misun Cho、Jeong Jea Seo、Jee Sun Yang、Soo Jin Oh、Kiho Lee、Song-Kyu Park、Hwan Mook Kim、Ho Jeong Kwon、Gyoonhee Han

  DOI：10.1021/jm3009376

  日期：2012.12.13

  Hydroxamate-based HDAC inhibitors have promising anticancer activities but metabolic instability and poor pharmacokinetics leading to poor in vivo results. QSAR and PK studies of HDAC inhibitors showed that a gamma-lactam core and a modified cap group, including halo, alkyl, and alkoxy groups with various carbon chain linkers, improved HDAC inhibition and metabolic stability. The biological properties of the gamma-lactam HDAC inhibitors were evaluated; the compound designated 8f had potent anticancer activity and high oral bioavailability.